EWA
SUPN icon

EverSource Wealth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

EverSource Wealth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21K Sell
69
-4,790
-99% -$230K ﹤0.01% 3497
2026
Q1 		$251K Buy
4,859
+7
+0.1% +$356 0.01% 929
2025
Q4 		$241K Buy
4,852
+3,435
+242% +$167K 0.01% 861
2025
Q3 		$67.7K Sell
1,417
-215
-13% -$8.66K ﹤0.01% 1488
2025
Q2 		$51.4K Buy
+1,632
New +$52.3K ﹤0.01% 1595
2025
Q1 		– Sell
-20
Closed -$723 – 4169
2024
Q4 		$723 Buy
+20
New +$704 ﹤0.01% 3072

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

EverSource Wealth Advisors's SUPN Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 99% in Q2 2026, selling an estimated $230K and leaving 69 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #3497.

EverSource Wealth Advisors first reported a position in SUPN in Q4 2024 and has held it in 6 quarters since. The position peaked at $251K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • EverSource Wealth Advisors held 69 shares of Supernus Pharmaceuticals worth $3.21K as of Q2 2026.
  • EverSource Wealth Advisors sold 4,790 Supernus Pharmaceuticals shares in Q2 2026, an estimated $230K.
  • Supernus Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3497 holding.
  • EverSource Wealth Advisors first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • EverSource Wealth Advisors's Supernus Pharmaceuticals position peaked at $251K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.